A multicentre, randomised, open-label, parallel-group Phase 2b study of belotecan versus topotecan for recurrent ovarian cancer
Sign Up to like & getrecommendations! Published in 2020 at "British Journal of Cancer"
DOI: 10.1038/s41416-020-01098-8
Abstract: Background This Phase 2b study compared the efficacy and toxicity of belotecan and topotecan in recurrent ovarian cancer. Methods Patients with platinum-sensitive recurrent or platinum-resistant recurrent ovarian cancer (PRROC) were randomised 1:1 to receive belotecan… read more here.
Keywords: belotecan topotecan; ovarian cancer; recurrent ovarian; cancer ... See more keywords